A combination of the anti-PD-1 antibody nivolumab and the anti-CTLA-4 antibody ipilimumab has been approved for treating melanoma, RCC, CRC with high microsatellite instability, and non-small cell lung cancer 42. The gene discussed is CTLA4; the disease is colorectal carcinoma.